Cas:52794-97-5 Carubicin Hydrochloride manufacturer & supplier

Chemical Name:Carubicin Hydrochloride

CAS.NO:52794-97-5

Synonyms:Carubicin Hydrochloride;5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-, (8S,10S)-, hydrochloride (1:1);(1S,3S)-3-Acetyl-3,5,10,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride (1:1);Carminomycin hydrochloride;(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride;Karminomycin hydrochloride;Caminomycin hydrochloride;5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-, hydrochloride, (8S-cis)-

Molecular Formula:C₂₆H₂₈ClNO₁₀

Molecular Weight:549.954

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:750.6ºC at 760mmHg

Density:1.63g/cm3

Index of Refraction:

PSA:196.84000

Exact Mass:549.140198

LogP:2.22820

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Carubicin Hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-, hydrochloride, (8S-cis)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Carminomycin hydrochloride Use and application,Karminomycin hydrochloride technical grade,usp/ep/jp grade.

Related News: Another critically important benefit of biocatalytic processes is that they are far more eco-efficient than conventional methods. This is because enzymes, being originally derived from natural products, generally perform best under mild (often ambient) conditions. 2H-1,4-Benzoxazine, 6-chloro-2-ethenyl-3,4-dihydro- manufacturers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, Guanidine, N’-cyano-N-hexyl-N,N’-dimethyl- suppliers Setting up of these plants will make the country self-reliant to a large extent in respect of these bulk drugs, it noted. 6β-[3-(4,5-dimethyl-furan-2-yl)-acryloylamino]-penicillanic acid vendor & factory.